COMP <GO>
DMRA vs OMER // NET PROFIT MARGIN
Damora Therapeutics Inc. (NASDAQ) VS. Omeros Corporation (NASDAQ) • 15-METRIC TALLY: DMRA 2
— OMER 2
■ METRIC PARITY
LAST: $22.01 (+1.85%) • MKT CAP: $1.36B
net-margins
—
LAST: $18.95 (+5.98%) • MKT CAP: $1.37B
net-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DMRA VS. OMER)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DMRA | OMER | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.49% | -8.47% | +7.98 | DMRA | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | DMRA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 53.6 | -3.74 | OMER | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.36B | $1.37B | -$13.0M | OMER | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DMRA REV | OMER REV | DMRA GROSS % | OMER GROSS % | DMRA FCF | OMER FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$6.7M | -$116.2M |
| FY 2024 | $0 | $0 | — | — | -$18.6M | -$149.0M |
| FY 2023 | $0 | — | — | — | -$36.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DMRA // BETA —
OMER // BETA —